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Abstract 
 
The leptin deficient ob/ob mice are insulin resistant and obese. However, the control 
of blood pressure in this model is not well defined. The goal of this study was to evaluate the 
role of leptin and of the renin-angiotensin system in the cardiovascular abnormalities 
observed in obesity using a model lacking leptin. To this purpose, we measured blood 
pressure in ob/ob and control animals by radiotelemetry combined with fast Fourier 
transformation before and after both leptin and enalapril treatment. Autonomic function was 
assessed pharmacologically. Blood pressure during daytime was slightly higher in the ob/ob 
compared to control mice while no difference in heart rate was observed. Blood pressure 
response to trimetaphane and heart rate response to metoprolol were greater in ob/ob mice 
than in control littermates indicating an activated sympathetic nervous system. Heart rate 
response to atropine was attenuated. Baroreflex sensitivity and heart rate variability were 
blunted in ob/ob mice, while low frequency of systolic blood pressure variability was found 
increased. Chronic leptin replacement reduced blood pressure and reversed the impaired 
autonomic function observed in ob/ob mice. Inhibition of angiotensin converting enzyme by 
enalapril treatment had similar effects, prior to the loss of weight. These findings suggest that 
the renin-angiotensin system is involved in the autonomic dysfunction caused by the lack of 
leptin in ob/ob mice and support a role of this interplay in the pathogenesis of obesity, 
hypertension, and metabolic syndrome. 
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Introduction 
Obesity, hypertension, dyslipidemia and diabetes type II are the main risk factors which 
characterize metabolic syndrome when present simultaneously [1]. In an attempt to correlate 
obesity, diabetes type II and hypertension, Landsberg postulated an interesting model in 
which blood pressure (BP) increase is thought to be an unfortunate result of mechanisms that 
establish energy balance and limit weight gain. Although compelling evidences tightly 
correlated these diseases, no adipose tissue derived molecule was taken into account [2]. In 
fact, obesity itself can activate the sympathetic and the renin-angiotensin system, resulting in 
BP increase [3]. It is well described that both rodents and humans with obesity have higher 
levels of leptin [4] an important hormone expressed and secreted by adipose tissue 
proportionally to its size [5]. Leptin acting centrally [6] decreases body weight and adipose 
tissue mass through inhibiting appetite and food intake [7]. Moreover, intracerebroventricular 
administration of leptin increases renal sympathetic nerve activation and arterial pressure [6]. 
However, we have recently shown that the leptin receptor deficient db/db mice had higher BP 
compared to control littermates, which was unexpectedly associated with increased 
sympathetic and attenuated parasympathetic drive [8], characterizing a cardiovascular 
autonomic dysfunction observed in obesity. In addition, since enalapril normalized the 
autonomic dysfunction in db/db mice, angiotensin II (AngII) may be involved. This peptide 
regulates BP through actions in peripheral tissues and in the brain by activating the 
sympathetic nervous system [9] and altering baroreflex heart rate (HR) regulation [10]. Db/db 
mice only lack one type of leptin receptor and may still be responsive to this hormone. Thus it 
could not be excluded that the high circulating leptin levels in db/db mice could be involved 
in the sympathetic activation and increased blood pressure (BP) in this model. To finally 
clarify the role of leptin and its relation to Ang II, we studied a model lacking leptin. 
Measurement of BP was performed in the leptin deficient ob/ob mice and control animals by 
 3
radiotelemetry combined with fast Fourier transformation before and after both leptin and 
enalapril treatment. Autonomic function was as well assessed pharmacologically.  
 
Methods 
Animals 
We studied adult 16-week-old, male ob/ob (B6.V-Lepob/J) mice and male ob/+ 
(C57BL/6J) purchased from Jackson Laboratory (Bar Harbor, ME, USA). The animals were 
maintained on a 12h light/12h dark cycle at 22°C and had free access to standard chow 
(0.25% sodium, SSNIFF Spezialitäten GmbH, Soest, Germany) and drinking water ad 
libitum. All experiments were conducted under these conditions. The local council on animal 
care approved the study according to requirements of the American Physiological Society. We 
measured body weights at weekly intervals. After recovery, telemetric baseline values were 
recorded for three days followed by enalapril (Sigma; 30mg/Kg.day) and by leptin (R&D; 
6μg/day) treatment in Alzet osmotic minipumps for 28 days. Enalapril was given to every 
mouse in the drinking water for seven days. A wash out period of seven days was allowed 
before osmotic minipumps containing leptin were implanted. After one week of leptin 
infusion, data were collected again.  
 
Pharmacological testing of autonomic function 
To evaluate autonomic control of BP, the following drugs were applied: muscarinic 
blockade was obtained with atropine (2 mg/kg; ob/+: n=8; ob/ob: n=6), β1-adrenergic receptor 
blockade with metoprolol (4 mg/kg; ob/+: n=6; ob/ob: n=5), and ganglionic blockade with 
trimetaphane (30 mg/kg; ob/+: n=5; ob/ob: n=5). All of the substances were given 
intraperitoneally in the morning hours between 9 am and 12 am. Continuous beat-by-beat 
values of BP were recorded for 1 hour, after which the drugs were applied. Thereafter, beat-
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by-beat values were recorded for 1 additional hour. As in a former study [11], the values from 
the 45th to the 60th minute after drug injection were used to characterize the respective 
responses to avoid the measurement of stress-induced BP and HR changes. The protocols for 
the single injections were separated by ≥24 hours. Drug administrations were not randomized. 
BP values in this study represent means of 3 days. 
 
Spectral Analysis 
Our approaches to radiotelemetry, spectral analysis, and calculations of baroreflex 
sensitivity (BRS) have been described elsewhere [11, 12]. For evaluation of cardiovascular 
function, the baroreceptor heart rate reflex and heart rate variability in the low frequency 
range (HRV-LF) were investigated using spontaneous changes in BP and HR. The power 
spectra of systolic blood pressure (SBP), pulse interval time series, and the cross spectra were 
calculated using fast Fourier transformation (FFT). Beat-to-beat values of detected R-R 
intervals and BP values were interpolated, low-pass filtered (cutoff 6 Hz) and re-sampled at 12 
Hz. Data segments of 43 seconds were used for spectral analysis. Linear trends were removed 
and power spectral density was estimated with the FFT-based Welch algorithm using 
segments of 512 data points with 50% overlapping and Hanning window. The power in the 
frequency range of low frequencies (LF: 0.25 to 0.6 Hz) was calculated. Five representative 
intervals were chosen for spectral analysis and averaged according to the following criteria 1) 
steady state conditions, 2) no large sudden BP changes, 3) no artifacts. The frequency bands 
were adapted for analysis in mice considering the ranges of HR rate and breathing frequencies 
[13]. 
 
Baroreflex sensitivity (BRS) 
Spontaneous baroreflex slope was calculated as the slope of the linear regression line 
between SBP and the subsequent R-R intervals using sequences defined as an episode of at 
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least three heart beats with more than 0.01 mmHg SBP per beat. The average values of all 
slopes with a correlation coefficient greater than 0.85 were calculated for sequences with 
rising BP (BRS- up). The BRS-LF was defined as the mean magnitude value of transfer 
function between SBP and R-R interval in the low-frequency band with negative phase and 
squared coherence value greater than 0.5. A negative phase indicates that BP leads R-R-
interval and a coherence value greater than 0.5 indicates a dominating linear relationship. The 
data analysis was performed with the PV-wave software (Visual Numerics, Houston, TX, 
U.S.A.). 
 
Statistics 
Data are presented as means ± SEMs. Statistically significant differences in mean 
values were evaluated by ANOVA followed by Bonferroni posthoc test. Unpaired Student t-
test was used independent samples. The value of P≤0.05 was considered significant. 
 
 
 
Results 
Non-dipping arterial hypertension in ob/ob mice 
In the beginning of the telemetry measurements, following adaptation and recovery 
periods after probe implantations, body weight values were higher in ob/ob (58.2 ± 0.7 g) 
when compared to ob/+ mice (29.4 ± 0.9 g). As previously described [14, 15], blood glucose 
levels were increased in ob/ob compared to ob/+ mice at 16 weeks of age. Day and night 
mean arterial pressure (MAP) and heart rate (HR) are shown in Figure 1. Daytime MAP was 
higher in ob/ob (112.5 ± 1.2 mmHg) when compared to the controls (104.2 ± 2.6 mmHg; 
P<0.05: Figure 1A). No difference in BP between the groups was observed during the active 
night period. Thus, ob/ob mice showed an abnormal diurnal BP dipping status as can be seen 
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by the reduction of the BP amplitude (6.9 ± 0.6 vs. 2.0 ± 0.2 mmHg). On the other hand, HR 
was not different between the groups at both day and night time, and showed a normal diurnal 
pattern (day: ob/+ = 484.7 ± 6.8 and ob/ob=511.1 ± 10.2 bpm; night: ob/+ = 527.6 ± 6.7 and 
ob/ob=551.6 ± 10.1 bpm: Figure 1B). 
 
Autonomic imbalance in ob/ob mice 
The activity of the autonomic nervous system was tested pharmacologically. BP 
response to trimetaphane and HR response to both atropine and metoprolol were measured. 
The ganglionic blockade with trimetaphane reduced blood pressure in both strains (-28.9 ± 0.9 
vs. -43.3 ± 2.5 mmHg; Figure 2A). However, the effect in obese mice was more pronounced 
than in controls (P<0.001). A lower HR response to atropine was observed in ob/ob mice 
compared to ob/+ (102.2 ± 3.6 vs. 64.8 ± 3.6 bpm; P<0.001; Figure 2B). β1-adrenergic 
receptor blockade  with metoprolol provoked a higher decrease in HR in ob/ob than in ob/+ 
mice (-37.8 ± 3.0 vs. -97.2 ± 6.0 bpm; P<0.001; Figure 2C). These results suggest increased 
sympathetic and decreased parasympathetic tone in ob/ob mice. Sympathetic modulation of 
vascular tone was also analysed by the low-frequency systolic BP (LF-SBP) oscillations, 
derived from the Fourier analyses of the telemetric BP data [16]. Along with the trimetaphane 
and metoprolol results, LF-SBP was found increased in ob/ob mice (2.5 ± 0.3 vs. 5.4 ± 1.1 
mmHg2; P<0.05; Figure 3A). In mice, low-frequency HR oscillations (LF-HRV) are mediated 
through parasympathetic mechanisms [17]. In obese mice, LF-HRV was attenuated which 
corresponds with the decreased response to atropine (4.8 ± 0.9 vs. 1.8 ± 0.6 msec2; P<0.05; 
Figure 3B). 
 
Reduced baroreflex in ob/ob mice 
The baroreflex HR regulation was assessed by the sequence method and cross-spectral 
analysis. We have previously proven the validity of spontaneous BP and HR changes to 
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characterize baroreflex sensitivity (BRS) in conscious mice [12]. BRS-up and BRS-LF were 
significantly decreased in ob/ob mice. Values for baroreflex sensitivity were substantially 
lower in ob/ob mice (BRS-up= 0.36 ± 0.10 msec/mmHg, Figure 3C; BRS-LF= 0.79 ± 0.19 
msec/mmHg, Figure 3D) compared to ob/+ animals (BRS-up= 1.09 ± 0.25 msec/mmHg and 
BRS-LF= 1.96 ± 0.47 msec/mmHg; P<0.05). 
 
Autonomic imbalance is reversed by chronic leptin treatment 
The same parameters were measured after one week of leptin treatment with osmotic 
minipumps. Leptin was given in a concentration (6µg/day) previously described to restore 
glucose levels [18]. Leptin levels increased in both groups after one week of infusion (normal 
levels: ob/+= 2.2 ± 0.7 and ob/ob= 0 vs. after leptin: ob/+= 23.1 ± 2.2 and ob/ob= 12.8 ± 3.6 
ng/mL). At this time point, body weight of ob/ob was 47.1 ± 1.2 g and ob/+ 29.7 ± 0.9 g.  
Figure 4 shows BP changes after leptin treatment in ob/ob and control animals. 
Infusion of leptin decreased BP in ob/ob but not significantly in control mice. After one week 
of leptin treatment, changes in MAP in ob/+ mice was -4.1 ± 1.6 mmHg and -10.5 ± 2.3 
mmHg in ob/ob mice (P<0.05). Leptin also increased baroreflex in both strains. Moreover, in 
leptin treated ob/ob mice BRS was restored to the values of ob/+ (BRS-LF: ob/+ before 
leptin: 1.9 ± 0.5 vs. ob/ob after leptin 2.5 ± 0.5; Figure 3D). LF-SBP was not changed after 
leptin treatment in the control animals. However, the increased LF-SBP observed in ob/ob 
mice was normalized by leptin (ob/+ baseline vs. ob/ob + leptin: 2.5 ± 0.3 vs. 1.8 ± 0.7 
mmHg2; Figure 3A). Complete interruption of efferent autonomic traffic with trimetaphane 
resulted in a more pronounced reduction of BP in ob/ob mice during baseline, as shown in 
Figure 2A. After leptin treatment, the effect of trimetaphane in obese animals was restored to 
the control baseline levels (ΔBP ob/+ baseline vs. ob/ob + leptin: -28.9± 0.9 vs. -24.2±1.2 
mmHg). 
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Autonomic imbalance is reversed by ACE inhibition 
Figure 5A shows the MAP changes during treatment with the angiotensin converting 
enzyme inhibitor enalapril, which had no effect on body weight. Enalapril reduced MAP in all 
animals and normalized circadian rhythm of BP in ob/ob mice. Furthermore, it significantly 
increased BRS-LF and LF-HRV and decreased LF-SBP (Figure 5B-D). In contrast, these 
parameters did not change significantly in control animals after treatment with enalapril. 
 
Discussion 
The major phenotypes of leptin deficient ob/ob mice are insulin resistance and obesity 
[19]. Often obesity is accompanied by a greater blood volume and increased cardiac output, 
which may lead to the development of hypertension [20]. This sequence of events may be the 
cause for the observed tight association between obesity and hypertension in most populations 
and suggests involvement of an adipose tissue-derived signal [21-23]. Leptin is the prime 
suspect because it was shown to elicit sympathetic activation when injected at high doses 
directly into the brain [24-26]. Indeed, circulating leptin concentrations are increased in 
patients with obesity and type 2 diabetes [27, 28]. Leptin levels are also augmented in 
nondiabetic patients with hypertension [29, 30]. Furthermore, mice that overexpress leptin 
have elevated tail-cuff systolic BP [31]. 
However, we have recently shown that the db/db mice, a model deficient in the major 
leptin receptor, exhibit elevated blood pressure (BP) associated with increased sympathetic 
and attenuated parasympathetic drive compared to the control littermates [8]. Nevertheless, 
the db/db mice express other isoforms of leptin receptors and exhibit high circulating leptin 
levels. Thus, the well-described leptin-induced sympathoactivation may be involved in the 
cardiovascular autonomic dysfunction observed in the db/db mice employing other receptors. 
To clarify this issue, we analyzed the cardiovascular regulation in ob/ob mice 
completely lacking leptin. In our hands, ob/ob mice had slightly but significantly higher BP 
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compared to the control littermates during the day. The published results about both acute and 
chronic BP measurements in ob/ob mice appear to be controversial. In several studies BP was 
evaluated 48 h after surgery, a time-frame not sufficient for stabilizing BP and day/night 
circadian rhythm. In contrast to previous findings but more according to our data, Swoap 
reported slightly increased blood pressure in ob/ob mice with levels of 108±2 mmHg 
compared to 100±2 mmHg in controls [32]. In that study, BP was also measured by telemetry 
like in ours. However, the telemetric devices were implanted into the aorta through the carotid 
artery which may have impaired the function of the carotid baroreceptors. For that reason and 
because our study focused on the autonomic regulation of blood pressure in the ob/ob mice, 
we implanted the telemetric device through the femoral artery. 
Similar to what we found in the leptin receptor deficient db/db mice, BP failed to drop 
during the inactive period in the ob/ob mice, a pattern that resembles non-dipping of BP often 
seen in hypertensive humans [33]. A disturbed circadian rhythm is often associated with 
metabolic disorders [34]. The Clock mutant mice, which lack a transcription factor involved 
in the generation of circadian rhythms, are hyperphagic and develop obesity. The resultant 
obesity is associated with increased blood glucose, cholesterol, and triglyceride levels, as 
observed in obese humans with metabolic syndrome [35]. Additionally, reduced circadian BP 
variation is associated with increased mortality [36].  
More importantly, we observed an imbalance of the autonomic nervous system in the 
ob/ob mice. Regardless of the total absence of leptin, a higher sympathetic tone was 
unexpectedly found in these animals. Although no direct measurements of sympathetic 
activity was performed, the stronger effect of metoprolol and trimetaphane in the ob/ob mice 
support that notion. Along with these findings, the parameter LF-SBP, which is believed to 
represent the sympathetic tone to the periphery, was found increased in the ob/ob animals.  
In a previous work, we underscored the validity of spontaneous BP and HR changes to 
characterize baroreflex sensitivity (BRS) in conscious mice [12], as shown previously in 
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humans [37]. Baroreflex is attenuated in the ob/ob mice as can be seen by a reduction of BRS-
up and BRS-LF. Vagal regulation is also reduced in the obese animals. HR increase in 
response to intraperitoneal injection of atropine was approximately 40% reduced in the ob/ob 
compared to the control mice. In keeping with that finding, LF-HRV was found attenuated in 
the obese mice. Altogether, our data shows that ob/ob mice at 16 weeks of age present 
alterations of the autonomic homeostatic mechanisms that regulate BP and HR.  
Chronic infusion of leptin reduced BP in our ob/ob mice probably by reducing 
sympathetic activity to the periphery. Accordingly, leptin infusion reduced the trimetaphane 
effect on BP and LF-SBP in ob/ob mice to the baseline level of control animals and 
normalized the altered baroreflex in these animals. Such reduction in BP by leptin has already 
been described in rats after intracerebroventricular infusion of the protein at low doses [38]. 
Taken together, our results suggest that leptin is not involved in the onset and maintenance of 
neither the obesity related hypertension nor the autonomic dysfunction related to type 2 
diabetes. In the opposite, the resistance to leptin often observed in obese and diabetic patients 
[39] may even be causal for the increased BP in analogy to the ob/ob and db/db mice. 
In contrast, the renin-angiotensin system seems to be involved in this phenotype. 
Angiotensin II regulates BP via peripheral and central mechanisms. Centrally, angiotensin II 
activates the sympathetic nervous system. Furthermore, angiotensin II alters baroreflex heart 
rate regulation. We analyzed the inhibition of ACE by enalapril in the ob/ob mouse model, 
since we had found increased ACE activity in db/db mice, which was later confirmed in 
another study [40]. ACE inhibition decreased BP in both groups and normalized the circadian 
rhythm in ob/ob mice suggesting that the increase in BP was at least in part due to the renin-
angiotensin system in this model. The associated improvement of baroreflex sensitivity and 
reducing sympathetic drive to the periphery by enalapril is consistent with a central 
mechanism. Markedly, inhibition of ACE had similar effects as leptin treatment in obese 
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mice. Nevertheless, enalapril treatment did not change body weight in both groups excluding 
the possibility that weight loss could influence and restore autonomic dysfunction.  
Our results show that blood pressure in the leptin deficient ob/ob mice is associated to 
an imbalance of the autonomic nervous system featured by sympathetic activation and 
reduction of the parasympathetic tone in association with diminished baroreflex sensitivity. 
Therefore, we conclude that ob/ob mice, like db/db mice [8], are a model for the 
cardiovascular autonomic neuropathy seen in diabetic and obese patients [24, 25, 41] 
predisposing them to target organ damage and cardiac arrhythmias and ultimately increasing 
morbidity and mortality.  
In conclusion, our data suggest that angiotensin II is involved in the autonomic 
imbalance associated with obesity and hypertension caused by leptin deficiency. 
 
Perspectives 
Our data suggesting that the renin-angiotensin system, but not leptin, is involved in 
non-dipping hypertension and autonomic imbalance related to obesity and type 2 diabetes 
may have experimental and clinical implications. Possibly the leptin resistance observed in 
patients is involved in the BP increase accompanying metabolic syndrome and obesity since 
we have unexpectedly shown that leptin reduces sympathetic activity and BP at least in ob/ob 
mice. Pharmacological activation of the leptin system or breaching of leptin resistance could, 
therefore, not only ameliorate obesity but also improve cardiovascular parameters. In 
addition, our data underscore the suitability of the RAS as drug target in the human metabolic 
syndrome. 
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Figure Legends 
Figure 1. Circadian variation of MAP (A) and HR (B) for ob/+ (n=6, white bars) and ob/ob 
(n=7, black bars) mice. MAP was higher in ob/ob mice only during the day. HR was higher in 
both groups at night (*P<0.05, **P<0.01). 
 
Figure 2. Effect of trimetaphane (30mg/Kg) on blood pressure (ΔMAP; A) and of atropine 
(2mg/Kg; B) and metoprolol (4mg/Kg; C) on HR in ob/+ (black bars) and ob/ob mice (white 
bars) (***P<0.001). 
 
Figure 3. Autonomic regulation in ob/ob mice (A) Low-frequency variability of systolic 
blood pressure (LF-SBP) indicating sympathetic outflow to the periphery. (B) Low-frequency 
heart rate variability (LF-HRV). (C) Spontaneous baroreflex sensitivity up-sequences (BRS-
up) calculated with the sequence method. (D) Spontaneous baroreflex sensitivity in the low 
frequency band (BRS-LF) calculated as the mean value of the transfer function between SBP 
and pulse intervals. All parameters were measured before and after leptin infusion in both 
groups (*P<0.05, **P<0.01, ***P<0.001). 
 
Figure 4. Leptin treatment of ob/ob mice. Change of mean arterial pressure (ΔMAP) by leptin 
treatment in ob/+ and ob/ob mice (*P<0.05). 
 
Figure 5. Effect of ACE inhibition with enalapril on blood pressure and autonomic function 
in ob/ob and ob/+ mice. (A) Circadian variation of mean arterial pressure (ΔMAP) in basal 
conditions and after enalapril treatment. (B) Low-frequency variability of spontaneous 
baroreflex sensitivity (BRS-LF). (C) Low-frequency systolic blood pressure variability (LF-
SBP). (D) Low-frequency heart rate variability (LF-HRV) (*P<0.05). 
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